Gilead Sciences Sees Surge in Institutional Investment

Pharmaceutical giant's stock boosted by major fund inflows in Q4

Mar. 29, 2026 at 11:33am

Got story updates? Submit your updates here. ›

Gilead Sciences, Inc. (NASDAQ:GILD) saw a massive 14,975% increase in institutional investment from USA Financial Formulas during the fourth quarter, according to a recent SEC filing. The biopharmaceutical company's stock has been a target of growing interest from major hedge funds and asset managers as it continues to expand its portfolio of antiviral and oncology treatments.

Why it matters

Gilead's ability to attract significant institutional investment signals growing confidence in the company's long-term growth potential. As a bellwether in the pharmaceutical industry, Gilead's performance is closely watched by analysts and investors alike, making this surge in fund inflows a notable development.

The details

According to the SEC filing, USA Financial Formulas increased its stake in Gilead Sciences by 14,975% during the fourth quarter, now owning 9,045 shares worth $1.11 million. This represents a sizable position for the firm, which views Gilead as the 29th largest holding in its investment portfolio.

  • The SEC filing was submitted on March 29, 2026, detailing Gilead's Q4 2025 institutional ownership changes.
  • Gilead Sciences reported its Q4 2025 earnings on February 10, 2026.

The players

Gilead Sciences, Inc.

A biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need, with a portfolio anchored by antiviral therapies for HIV and viral hepatitis.

USA Financial Formulas

An investment management firm that significantly increased its stake in Gilead Sciences during the fourth quarter of 2025.

Got photos? Submit your photos here. ›

What’s next

Gilead Sciences is expected to provide an update on its pipeline and financial guidance when it reports its full-year 2026 results in early 2027.

The takeaway

Gilead Sciences' ability to attract significant institutional investment, even as a large-cap pharmaceutical company, underscores the market's confidence in the firm's growth prospects. This surge in fund inflows signals that major investors see long-term value in Gilead's diversified drug portfolio and R&D capabilities.